Waters (WAT) Aandelenoverzicht
Waters Corporation biedt analytische workflowoplossingen in Azië, Noord- en Zuid-Amerika en Europa. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
WAT Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Waters Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$410.01 |
| 52 Week Hoogtepunt | US$426.22 |
| 52 Week Laag | US$282.77 |
| Bèta | 1.19 |
| 1 maand verandering | -0.52% |
| 3 maanden verandering | 13.72% |
| 1 Jaar Verandering | 37.11% |
| 3 jaar verandering | 49.97% |
| 5 jaar verandering | 3.59% |
| Verandering sinds IPO | 10,743.24% |
Recent nieuws en updates
Narratiefupdate • Sep 03
WAT: Clinical Diagnostics Expansion And Share Repurchases Will Support Steady Profitability
Analysts have modestly lifted their price target for Waters to $439.70 from $413.26. This reflects updated assumptions that combine a lower revenue growth outlook with a slightly higher projected profit margin and a broadly unchanged future P/E multiple.
Narratiefupdate • Aug 13
WAT: Omics Platforms And Q2 Earnings Momentum Will Drive Future Upside
Analysts have raised their price target for Waters to $475 from $460. This change reflects updated assumptions on revenue growth, profit margins and future P/E, which slightly adjust the stock's risk and return profile.Recent updates
Narratiefupdate • Sep 03
WAT: Clinical Diagnostics Expansion And Share Repurchases Will Support Steady Profitability
Analysts have modestly lifted their price target for Waters to $439.70 from $413.26. This reflects updated assumptions that combine a lower revenue growth outlook with a slightly higher projected profit margin and a broadly unchanged future P/E multiple.Narratiefupdate • Aug 13
WAT: Omics Platforms And Q2 Earnings Momentum Will Drive Future Upside
Analysts have raised their price target for Waters to $475 from $460. This change reflects updated assumptions on revenue growth, profit margins and future P/E, which slightly adjust the stock's risk and return profile.Narratiefupdate • Jul 30
WAT: Clinical Diagnostics Expansion And Biotech Tools Portfolio Will Support Steady Profitability
Analysts modestly raised their price target for Waters to $413 per share from $402. This change reflects updated views on fair value, a slightly lower discount rate, and small revisions to long term revenue growth, profit margin and future P/E assumptions.
Narratiefupdate • Jul 16
WAT: BD Acquisition And Diagnostics Expansion Will Likely Support Measured Upside
Analysts have raised their price target for Waters from $330.00 to about $358.57, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that together support a higher valuation framework for the stock. What’s in the News for Waters Waters Corporation is scheduled to release its second quarter 2026 earnings before the market opens on August 4, with analysts expecting EPS of $3.01, which is 2% higher year over year.Seeking Alpha • Jul 14
Waters Corporation Is Getting Awfully Pricey
Summary Waters Corporation remains a Hold as valuation concerns are balanced by ongoing synergy capture from its Becton, Dickinson acquisition. WAT's Q1 pro forma sales rose to $1.54B, with legacy revenue up 13% and recurring revenue surging 123%, signaling broad-based growth. Synergy realization is on track, with $55M+ cost savings and $50M revenue synergies targeted for 2026, supporting incremental EBITDA gains. Despite high absolute multiples, WAT trades at the low end of peer valuations, but further stock appreciation or weak fundamentals could trigger a bearish reassessment. Read the full article on Seeking AlphaNarratiefupdate • Jul 02
WAT: AI Immune Profiling Partnership And Biotech Tools Will Support Steady Profitability
Analysts have nudged their price target on Waters higher to about $402 from roughly $393, citing updated assumptions that include an adjusted discount rate of 8.24%, revenue growth expectations of 27.01%, a profit margin estimate of 16.78%, and a forward P/E of 47.17x. What’s in the News for Waters Waters and IMU Biosciences formed a partnership that combines Waters Biosciences flow cytometry and single cell technologies with IMU’s AI and machine learning platform to support high definition immune profiling across discovery, translational, and clinical research.Narratiefupdate • Jun 18
WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside
Analysts maintained their $460.00 price target on Waters, citing relatively steady assumptions around revenue growth, profit margin, and future P/E, which offset the slightly higher discount rate in their valuation work. What’s in the News for Waters Waters launched the TA Instruments Coin Cell Differential Scanning Calorimeter, combining thermal, evolved gas, and electrochemical analysis in a single experiment to support earlier insights into battery thermal runaway and reduce cell teardown time by over 90% (source: company announcement, 9 June 2026).Analyse-artikel • Jun 16
Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance
Waters (WAT) is in focus after launching its BioResolve Peptide and GTxResolve Lipid columns and securing FDA 510(k) clearance for the BD BACTEC FXI Culture System, developments that expand its biopharma and diagnostics footprint. See our latest analysis for Waters. Despite the product launches and diagnostics clearance, Waters’ share price shows mixed momentum, with a 30 day share price return of 9.51% and a 90 day share price return of 22.20%, while the 1 year total shareholder return sits...Narratiefupdate • Jun 03
WAT: New Omics Platforms And Buybacks Will Support Future Upside
Analysts have trimmed their price target for Waters to $460, reflecting slightly higher assumed discount rates, modestly adjusted long term revenue growth and profit margin expectations, and a lower future P/E multiple in their updated models. What's in the News Waters launched the Cyclic IMS P20 Mass Spectrometer, a structural and spatial omics platform using multipass Cyclic Ion Mobility Spectrometry and advanced fragmentation and imaging techniques, aimed at earlier detection of disease signals and more detailed molecular visualization.Analyse-artikel • May 19
Earnings Troubles May Signal Larger Issues for Waters (NYSE:WAT) Shareholders
Investors weren't pleased with the recent soft earnings report from Waters Corporation ( NYSE:WAT ). We did some...Narratiefupdate • May 18
WAT: New Product Launches And Completed Buybacks Will Support Future Upside
Analysts now set a slightly higher price target for Waters at about $478, up from about $470, reflecting updated views on its fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Waters issued earnings guidance for the second quarter of 2026, with expected total revenue between US$1.616b and US$1.631b, and for full year 2026, with expected total revenue between US$6.405b and US$6.455b on a reported basis (Corporate guidance).Narratiefupdate • May 01
WAT: New Instrument Launches And Reorganized Divisions Will Support Future Upside
Analysts have trimmed their price target on Waters from $480 to $470, citing updated assumptions for significantly higher revenue growth at 37.91%, a profit margin of 17.88%, a prospective P/E of 47.70 and a discount rate of 7.89%. What's in the News Waters plans to globally launch the omniDAWN Multi Angle Light Scattering Photometer in summer 2026, targeting UHPLC and UPLC workflows for absolute molar mass and size measurements across complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials (Key Developments).Narratiefupdate • Apr 17
WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check
Analysts have kept their price target for Waters steady at $330.00, citing updated assumptions for slightly higher revenue growth, a wider profit margin, and a higher future P/E multiple as the key drivers behind the unchanged fair value view. What's in the News Launched the Waters omniDAWN Multi-Angle Light Scattering Photometer for UHPLC and UPLC workflows, targeting absolute molar mass and size measurements for complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials.Narratiefupdate • Apr 03
WAT: New Four Division Model And Materials Focus Will Support Higher Profitability
Analysts have reduced their price target on Waters by about $5 to $393, reflecting small adjustments to fair value assumptions, discount rate, revenue growth, profit margin and future P/E inputs. What's in the News Waters launched the TA Instruments ARES-G3 Rheometer, a next generation system that captures up to 25,000 data points per second, aims to shorten standard test times by up to 80%, and is available for order as part of the materials characterization portfolio (Key Developments).Narratiefupdate • Mar 20
WAT: New Four Division Model Will Support Higher Long Term Profitability
Analysts have kept their price target for Waters steady at $398.05. This reflects updated views on a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E assumption.Narratiefupdate • Mar 05
WAT: New Four Division Structure Will Support Higher Long Term Earnings
Analysts have nudged their price target for Waters higher to $398.05 from $394.68, reflecting updated assumptions that combine a higher revenue growth outlook, a lower projected profit margin, and a richer future P/E multiple. What's in the News Waters has closed a transaction and reorganized into four divisions, aligning its operations with high volume testing in regulated applications and adjacent markets such as therapeutics, food, environmental testing, and specialty diagnostics (Key Developments).Narratiefupdate • Feb 19
WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now
Analysts now mark their price target for Waters at $330, down from $349, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E that change their overall valuation framework. What's in the News Waters closed a transaction and reorganized into four divisions focused on high-volume testing and adjacent markets, now grouped as Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences (company announcement).Narratiefupdate • Feb 05
WAT: New Detector Launch And Higher Margins Will Likely Disappoint Optimists
Analysts have modestly lifted their price target for Waters to about $349, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E as the key drivers of this small adjustment from roughly $348.15. What's in the News Waters has scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat in the United States (Key Developments).Narratiefupdate • Jan 22
WAT: New Detector Launch And Stable Margins Will Support Future Upside
Analysts kept their price target for Waters steady at US$480.00, with only very small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, reflecting fine-tuning rather than a major shift in their view. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held via proxydocs.com/wat in the United States (company event filing).Narratiefupdate • Jan 08
WAT: Higher Margins And New Product Launch Will Support Future Upside
Analysts have lifted their price target on Waters to US$480 from about US$424, citing updated assumptions for slightly higher revenue growth, profit margins near 26%, and a modestly higher future P/E multiple. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat (Special/Extraordinary Shareholders Meeting).Analyse-artikel • Jan 04
Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)
Key Insights Waters' estimated fair value is US$362 based on 2 Stage Free Cash Flow to Equity Waters' US$382 share...Narratiefupdate • Dec 25
WAT: Future Product Expansion Will Likely Fail To Justify Current Optimism
Analysts have raised their price target on Waters from 300.00 dollars to 348.15 dollars, citing slightly stronger expectations for revenue growth, profit margins, and future valuation multiples. What's in the News Launched a new Charged Aerosol Detector optimized for Empower Software, expanding capabilities for measuring analytes with little or no UV absorption across pharmaceuticals, food, and environmental testing, with shipments expected by April 2026 (company product announcement).Narratiefupdate • Dec 10
WAT: Future Margin Gains And New Instruments Will Support Measured Earnings Outlook
Narrative Update on Waters Analysts have modestly raised their price target on Waters by approximately $6 per share, reflecting slightly lower discount rate assumptions, a small improvement in projected profit margins, and a marginally higher future P/E multiple that together support a higher fair value estimate. What's in the News Launched a new Charged Aerosol Detector, purpose built for Empower chromatography software, expanding Waters portfolio of LC detectors and strengthening its position in compliant, high sensitivity analysis for low UV analytes, with shipments expected by April 2026 (Key Developments) Unveiled the Xevo Charge Detection Mass Spectrometer to enable high resolution characterization of very large biomolecules that are central to next generation therapeutics, leveraging technology acquired from Indiana University and Megadalton Solutions (Key Developments) Raised full year 2025 guidance and now expects constant currency sales growth of 6.7% to 7.3% and GAAP EPS of 11.10 to 11.20 dollars per diluted share (Key Developments) Issued new guidance for the fourth quarter of 2025, targeting constant currency sales growth of 5.0% to 7.0% and GAAP EPS of 4.10 to 4.20 dollars per diluted share (Key Developments) Completed its multi year share repurchase program announced in January 2019, buying back more than 15.1 million shares for approximately 3.8 billion dollars in total consideration (Key Developments) Valuation Changes The fair value estimate has risen slightly to approximately $395 per share from about $389 per share, reflecting modest valuation upside.Narratiefupdate • Nov 26
WAT: Future Margins And Expanded Guidance Will Offset Slower Revenue Trends
Narrative Update on Waters: Analyst Price Target Revision Analysts have raised their price target for Waters, increasing the fair value estimate by $5.71 to $388.58. This revision is attributed to improved profit margin projections, even as revenue growth expectations have slowed.Narratiefupdate • Nov 07
WAT: Revenue Momentum And Expanded Guidance Will Balance Margin Risks Ahead
Analysts have raised their price target for Waters from $355.74 to $382.87. They cite significantly higher expected revenue growth, which outweighs a slight decrease in projected profit margins.Narratiefupdate • Oct 23
Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities
Narrative Update on Waters Analysts have slightly raised their price target for Waters from $351.07 to $355.74. This change is attributed to modest improvements in projected revenue growth and fair value estimates.Narratiefupdate • Oct 09
Pharmaceutical R&D And Merger Will Unlock Future Market Potential
Analysts have raised their price target for Waters to $351.07 from $347.14, citing expectations of stronger profit margins and steady revenue growth ahead. What's in the News Waters Corporation raised its earnings guidance for the full year 2025 and projects constant currency sales growth between 5.5% and 7.5%.Analyse-artikel • Sep 19
Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)
Waters Corporation's ( NYSE:WAT ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right now...Narratiefupdate • Sep 04
Pharmaceutical R&D And Merger Will Unlock Future Market Potential
With no changes in revenue growth expectations or discount rate, Waters’ fair value estimate remains stable, as reflected in the unchanged consensus analyst price target of $350.24. What's in the News Completed buyback program with 15,195,844 shares repurchased for $3,790.62 million, representing 22.96% of shares.Seeking Alpha • Feb 21
Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern
Summary Waters Corp reported better-than-expected Q4'24 and FY'24 results, driven by strong performance in academia, government, and pharma segments, despite FX headwinds impacting gross margins. The company anticipates continued growth in 2025, with projected revenue growth between 4.5% and 7%, supported by emerging markets like India and high-growth areas like GLP-1 and PFAS testing. Risks include elevated valuations and limited opportunities for cash deployment, making buybacks less attractive; current valuation appears challenging compared to historical averages and peers. I rate Waters Corp as a 'hold' due to solid recovery and growth potential, but caution investors to consider the premium pricing relative to value. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
Weighing In On Waters Corporation: Facing A Valuation Headwind
Summary Today, we take a more in-depth look at Waters Corporation, which provides analytical workflow solutions, primarily to the Pharma and Industrial industries. WAT stock has surged 35% since July lows, but analysts are growing increasingly cautious due to valuation concerns, with mixed ratings and tepid price targets. From a historical perspective, the equity now trades at the very top of its historical P/S and P/E ratios. Can WAT shares rally with this valuation headwind? An analysis of Waters Corporation follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Waters Corp: Short Reinvestment Runway Diminishes High Multiples
Summary Despite a 13% stock appreciation, I maintain a neutral stance on Waters Corporation due to factors outlined in this report. Q3 FY'24 results show mixed regional performance, with China sales still a drag on performance. Opportunities to redeploy surplus funds at an advantage appear limited, reducing compounding ability. Read the full article on Seeking AlphaRendement voor aandeelhouders
| WAT | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 0.2% | -1.9% | -0.9% |
| 1Y | 37.1% | 25.4% | 13.9% |
Rendement versus industrie: WAT overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 25.4 % opleverde.
Rendement versus markt: WAT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 13.9 %.
Prijsvolatiliteit
| WAT volatility | |
|---|---|
| WAT Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: WAT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van WAT is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1958 | 7,900 | Udit Batra | www.waters.com |
Waters Corporation levert analytische workflowoplossingen in Azië, Noord- en Zuid-Amerika en Europa. Het bedrijf opereert via twee segmenten, Waters en TA. Het bedrijf ontwerpt, produceert, verkoopt en onderhoudt systemen voor vloeistofchromatografie en massaspectrometrie (MS) en ondersteunt producten, waaronder chromatografiekolommen en andere verbruiksartikelen.
Waters Corporation Samenvatting
| WAT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$40.12b |
| Inkomsten(TTM) | US$166.63m |
| Inkomsten(TTM) | US$4.64b |
241.8x
Koers/Winstverhouding8.7x
P/S-verhoudingIs WAT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| WAT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$4.64b |
| Kosten van inkomsten | US$2.03b |
| Brutowinst | US$2.62b |
| Overige uitgaven | US$2.45b |
| Inkomsten | US$166.63m |
Laatst gerapporteerde inkomsten
Jul 04, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.70 |
| Brutomarge | 56.34% |
| Nettowinstmarge | 3.59% |
| Schuld/Eigen Vermogen Verhouding | 33.6% |
Hoe presteerde WAT op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/14 21:26 |
| Aandelenkoers aan het einde van de dag | 2026/09/14 00:00 |
| Inkomsten | 2026/07/04 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Waters Corporation wordt gevolgd door 44 analisten. 24 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Charles Butler | Barclays |